Insights from the PSCI Audit Findings 2025: Manufacturing Excellence in the Pharma Supply Chain
THE PSCI PRESENTS ITS ANNUAL PUBLIC AUDIT FINDINGS REPORT, PROVIDING CONTINUED INSIGHTS INTO SUPPLIER RISKS, TRENDS, AND AREAS FOR IMPROVEMENT ACROSS THE PHARMACEUTICAL AND HEALTHCARE SUPPLY CHAIN.
Pharmaceutical and healthcare companies run thousands of audits of their suppliers’ sites annually. Audits typically require between two to four days of focused, on-site effort from both the auditor and the supplier. PSCI members work together to share these audits, in support of greater transparency and valuable efficiencies that benefit both members and suppliers.
This report shares our analysis of findings from PSCI audits available on our platform. Each year, we review these in line with the PSCI Principles to identify trends, highlight improvements, and share recommendations. PSCI work with member companies, suppliers, and regional partners to turn analysis into practical guidance, training, and peer learning that suppliers can implement quickly. Overall, this analysis provides deep insight into supplier practices within the pharmaceutical and healthcare industry and suggests where collaborative efforts will have the greatest impact, guiding us on developing targeted resources and trainings.
This year’s report analyzes 2,046 findings from 228 supplier audits uploaded to the PSCI platform in 2024. These findings are categorised into 428 Governance & Management Systems findings, 26 Ethics findings, 273 Human Rights findings, 1,098 Health & Safety findings, and 221 Environment findings, offering a comprehensive overview of supplier practices and opportunities for improvement. The report includes a summary of findings across key topics, as well as a regional analysis looking at patterns across China, India, US, Western Europe, and other regions represented in this year’s uploads, presenting recommended actions for suppliers.